In addition, we show for the first time that tau is of clinical significance in Huntington’s disease through our finding that MAPT H2 haplotype affects the rate of cognitive decline in a large cohort of patients with Huntington’s disease, with evidence of some interaction with CAG repeat length. Here, MAPT is linked to juvenile Huntington disease.